Zacks: Ayala Pharmaceuticals, Inc (NASDAQ:AYLA) Given $21.13 Average Target Price by Brokerages
Ayala Pharmaceuticals, Inc (NASDAQ:AYLA) has received an average broker rating score of 1.75 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation, one has given a buy recommendation and two have assigned a strong buy recommendation to the company.
Brokers have set a 1 year consensus price target of $21.13 for the company and are forecasting that the company will post ($0.53) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Ayala Pharmaceuticals an industry rank of 85 out of 254 based on the ratings given to its competitors.
A number of brokerages have weighed in on AYLA. Citigroup initiated coverage on shares of Ayala Pharmaceuticals in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $25.00 price target on the stock. Jefferies Financial Group initiated coverage on shares of Ayala Pharmaceuticals in a research note on Tuesday, June 2nd. They set a “hold” rating on the stock. Raymond James assumed coverage on Ayala Pharmaceuticals in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $24.00 price target for the company. Finally, Oppenheimer initiated coverage on Ayala Pharmaceuticals in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $23.00 price objective on the stock.
Ayala Pharmaceuticals (NASDAQ:AYLA) last released its quarterly earnings results on Monday, June 22nd. The company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.68). The firm had revenue of $1.00 million for the quarter. Sell-side analysts predict that Ayala Pharmaceuticals will post -2.53 EPS for the current year.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.